“Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials”. 2022. SKIN The Journal of Cutaneous Medicine 6 (2): s4. https://doi.org/10.25251/skin.6.supp.4.